MiNK-413 / Agenus - LARVOL DELTA

MiNK-413: a Next generation armored allogenic BCMA CAR iNKT product (SITC 2022) - "In our native iNKT cell (agenT-797) clinical trials for COVID, solid tumors and Multiple Myeloma we observe excellent tolerability to up to 1 billion cell dosing with minimal treatment-related adverse events, absence of signs of CRS or peripheral neuropathy, and early signs of biological activity. MiNK-413 is eligible to target a broader rrMM patient population due to intrinsic iNKT cell properties such as effective bone-marrow homing, high BCMA specific activity augmented by natural CD1d and NK receptor-ligand mediated activity. We believe MiNK-413 will provide additional benefits to rrMM patients beyond currently available treatments."

Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor • IL15

MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline (GlobeNewswire) - "MiNK Therapeutics...announced the presentation of new data from five presentations at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting....MiNK-413 demonstrates superior tumor clearance in a systemic multiple myeloma models, compared to control BCMA-CAR. Armoring MiNK-413 with soluble IL-15 enables prolonged persistence, which may translate to increased durability in patients."

Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology

MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial Results (GlobeNewswire) - "Five abstracts accepted for presentation at Society of Cancer Immunotherapy 37th Annual Meeting, November 8th to 12th: (i) Clinical data from agenT-797 (allo-iNKTs) alone or in combination with anti-PD-1 in advanced solid tumor cancers, severe viral ARDS, and relapsed/refractory multiple myeloma; (ii) Data on our new therapeutic candidates, MiNK-215, a novel FAP-CAR-iNKT, and MiNK-413, a differentiated allogeneic armored-BCMA-CAR-iNKT; (iii) First reports of novel mechanisms of agenT-797, improving effector functions within the tumor microenvironment."

Clinical data • Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor

MiNK Selected for Five Presentations at Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting (GlobeNewswire) - "MiNK Therapeutics, Inc...announced the acceptance of five abstracts for presentation at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting, to be held November 8 – 12th, 2022."

P1 data • Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor

MiNK Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire) - "Engineered BCMA-CAR-iNKT and stromal-CAR-iNKT (undisclosed target) have demonstrated potent anti-tumor activity; IND enabling underway with target IND in 2022."

IND • Oncology

Identification and Characterization of an allogeneic iNKT-CAR targeting BCMA (SITC 2021) - "Furthermore, using a multiple myeloma in vivo xenograft model, infusion of agenT-F6 iNKT cells showed comparable tumor control to a clinical-stage BCMA CAR reference. Conclusions MiNK therapeutics is developing the next generation allogeneic CAR-iNKT therapies by using 1) a CAR discovery platform that allows more rapid and efficient identification of antigen-specific and biologically potent CAR candidates and 2) an iNKT cell platform naturally lacking alloreactivity that allows rapid engineering and expansion of an off-the-shelf CAR product."

Hematological Malignancies • Multiple Myeloma • Oncology